EyeGate is a clinical stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP , the company s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.
Quote | Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG)
Last: | $35.9152 |
---|---|
Change Percent: | 0.01% |
Open: | $35.9152 |
Close: | $35.9152 |
High: | $35.9152 |
Low: | $35.9152 |
Volume: | 2,164 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG)
2024-05-01 07:34:08 ET More on AB Corporate Bond ETF Dividend scorecard for AB Corporate Bond ETF Read the full article on Seeking Alpha For further details see: AB Corporate Bond ETF goes ex dividend today
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
Message Board Posts | Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG)
Subject | By | Source | When |
---|---|---|---|
KPRX is the new symbol. Have traded | PennyStockTrader2 | investorshub | 11/16/2021 12:37:45 AM |
Was starting to look at getting back in | BooDog | investorshub | 10/22/2021 4:56:46 PM |
Looking good. 20dma crossing the 50dma. 200 | BooDog | investorshub | 10/07/2021 3:32:50 PM |
STRONG BUY $11 TARGET | BooDog | investorshub | 10/05/2021 10:54:48 AM |
1.85 looks good to me. $$$ boogie | BooDog | investorshub | 10/04/2021 9:40:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...